Search results
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 5 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 3 days agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 6 days agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
Nucleus RadioPharma secures Series A investment from AstraZeneca
BioPharma-Reporter· 2 days agoThe investment from AstraZeneca marks a strategic move to further expand Nucleus's capabilities in developing targeted radiotherapies and theranostics, aimed at making cancer ...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 3 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 4 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 21 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 3 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...